We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

14 hedge funds and large institutions have $11.8M invested in Regencell Bioscience in 2025 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,090% more capital invested

Capital invested by funds: $281K → $11.8M (+$11.5M)

450% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 2

180% more funds holding

Funds holding: 5 → 14 (+9)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

0.07% more ownership

Funds ownership: 0.07% → 0.14% (+0.07%)

Holders
14
Holders Change
+9
Holders Change %
+180%
% of All Funds
0.18%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
2
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.61M
2
Squarepoint
Squarepoint
New York
+$1.22M
3
SSA
Schonfeld Strategic Advisors
New York
+$635K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$549K
5
UBS Group
UBS Group
Switzerland
+$458K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$63.5K
2
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
-$30K
3
TRCT
Tower Research Capital (TRC)
New York
-$22.3K

RGC Hedge Fund Activity: Q2 2025 in Review

14 of the 7,614 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q2 2025, worth a combined $11.8M — up 4,090% from $281K a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new RGC positions and 2 closed out — a net gain of 9 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Geode Capital Management, adding an estimated $1.61M. The largest seller was BlackRock, cutting an estimated $63.5K.

  • 14 institutional investors held Regencell Bioscience (RGC) as of Q2 2025, up from 5 in Q1 2025.
  • Funds reported $11.8M of Regencell Bioscience stock for Q2 2025, up 4,090% quarter-over-quarter.
  • 11 funds opened new Regencell Bioscience positions in Q2 2025 and 2 closed out, a net change of +9 holders.
  • The largest Regencell Bioscience buyer in Q2 2025 was Geode Capital Management, an estimated $1.61M added.
  • The largest Regencell Bioscience seller in Q2 2025 was BlackRock, an estimated $63.5K sold.

Based on aggregated 13F filings for Q2 2025.